 |
Bridge to Life Ltd. plans to generate revenue by selling Belzer UW™ brands of cold storage and kidney perfusion solutions and use those revenues to help pay for animal and clinical studies to develop a very promising patented new technology—fusogenic liposomal ATP, that transports high volumes of ATP into cells. ATP is essential for cell and organ health. Early animal studies show that fusogenic liposomal ATP may improve the condition of organs to be transplanted that would be a substantial advance in organ transplantation. Other potential applications are in heart attacks, cardiovascular surgery, and tourniquet surgery.
 |
Cambria Pharmaceuticals is focused on the discovery of innovative treatments for serious and progressively disabling neurological disorders. The Company exploits recent discoveries in the genetic basis of these disorders to engineer novel disease models and identify first-in-class, disease-modifying compounds. Cambria leverages collaborative relationships with academic institutions and patient-focused foundations to advance its programs in ALS (Lou Gehrig's disease) and other serious neurological diseases.
 |
Centrose is in business to discover novel drug leads using CarboConnect™, a proprietary discovery platform that rapidly enhances drugs and drug leads through the chemical and/or enzymatic attachment of "unusual sugars". Through CarboConnect, Centrose develops improved, proprietary versions of existing drugs and drug leads with large market potential and where significant unmet medical needs exist. Up until now, no one had exploited the potential of "unusual sugars" in drug discovery. The Company's first sugar enhanced lead has shown strong efficacy against one of the most aggressive tumor types known – non-small cell lung cancer.
 |
Colby is a clinical stage cancer therapeutic drug company developing small molecule drugs that modulate key metabolic Oxidative Stress (OS) pathways in prostate inflammation & cancer (PCa). Colby is bringing its lead drugs into the PCa clinic in 2008 & 2009, respectively. These drugs are being developed with access to grants from the National Institutes of Health, Department of Defense, the Prostate Cancer Foundation, and from funds from private investors. Colby has in-licensed these drugs from the Wisconsin Alumni Research Foundation (WARF). Colby operates in Sunnyvale & Menlo Park, CA and has collaborations in Wisconsin.
 |
ConjuGon®, Inc. is developing novel technologies for the prevention and treatment of bacterial infections. The rise of antibiotic-resistant, pathogenic bacteria is quickly becoming a crisis and many times, these infections are acquired when patients are treated in hospitals and other healthcare facilities for unrelated conditions. ConjuGon's® first product to prevent Catheter-Associated Urinary Tract Infections will soon enter Phase 1 human clinical trials and a second product for wound infections is in preclinical testing. ConjuGon® is based in Madison, Wisconsin and has licensed proprietary technology from leading institutions such as the University of Wisconsin-Madison and Baylor College of Medicine.
 |
Deltanoid Pharmaceuticals, Inc. was founded in 1999 by Drs. Hector DeLuca and Margaret Clagett-Dame, two leading research scientists in biochemistry at the University of Wisconsin – Madison to ensure that promising technologies, that have the potential to improve human health, are developed for commercialization. Deltanoid Pharmaceuticals is a drug development company involved in breakthrough treatments for osteoporosis, renal disease, psoriasis and other disease targets. The company specializes in designing advanced vitamin D analogs, and several of its vitamin D-based therapies are already being tested in human clinical trials. Deltanoid will develop therapies through early stage human trials and will then seek partners to conduct later stage human trials and commercialize the products.
 |
FluGen Inc. was established in 2007 to develop faster and more effective ways to prevent and treat pandemic and seasonal influenza. The Company leverages technologies from the laboratories of Dr. Yoshihiro Kawaoka, one of the world's foremost authorities on influenza. FluGen is located in the University Research Park and has access to high level BSL-3 and GMP manufacturing facilities. FluGen's business is focused on high yield vaccine manufacturing, pandemic and seasonal vaccine candidates and therapeutics for treating influenza.
 |
NeuroGenomeX (NGX), Inc. is an early stage company developing a drug, 2-deoxy-D-glucose (2DG), for patients with intractable epilepsy. Three million people in the US have epilepsy. Half of these people still experience seizures even with taking current medications. Because 2DG has a different mechanism of action compared to currently marketed epilepsy drugs, NGX believes 2DG may significantly reduce seizure frequency in intractable epilepsy patients. 2DG has positive results in 4 different animal models of epilepsy that are very predictive of human efficacy. The Company plans to be in human clinical trials by the end of 2009.
 |
ProCertus BioPharm is an oncology-based pharmaceutical company whose primary mission is to protect cancer patients against the side effects of chemotherapy and radiotherapy.
 |
Quintessence Biosciences is a private, preclinical stage biopharmaceutical company developing novel, proprietary, anti-cancer compounds based on its EVade™ ribonuclease technology platform. The company expects to initiate clinical studies with its first lead compound (QBI-139) in 2008 targeting solid tumors, such as colon and lung cancer. In vitro and in vivo preclinical data to date has demonstrated an excellent efficacy profile in murine xenograft models relative to marketed anti-cancer drugs. Additional anti-cancer drug candidates using targeting mechanisms and other mechanisms to enhance the pharmacokinetic profile of EVade™ Ribonucleases are under development.
